Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views?

While Wall Street analysts give Viking Therapeutics (VKTX) a strong buy recommendation with an average brokerage rating of 1.30, the article cautions that brokerage recommendations often have a positive bias and may not reliably predict stock performance. The Zacks Rank system, which relies on earnings estimate revisions, rates VKTX as a Hold (#3), suggesting investors should be cautious despite the bullish analyst sentiment.